Saturday, July 11, 2026

Patent intelligence · US

US 8884034

TOFA analogs useful in treating dermatological disorders or conditions

granted A61KA61K31/341A61K31/351A61K31/365
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 8
Applicant portfolio 308
Patent details — US 8884034
Jurisdiction
US
Status
granted
Grant date
Nov 11, 2014
Expiration
Nov 6, 2034
Claims
13
CPC classes
A61K, A61K31/341, A61K31/351, A61K31/365
View on Google Patents ↗

Quick answer

US 8884034 (TOFA analogs useful in treating dermatological disorders or conditions) is held by Dermira (Canada), Inc.. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/341, A61K31/351, A61K31/365, A61K31/4025, A61K31/4525

More from Dermira (Canada), Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 8884034?

US 8884034 (TOFA analogs useful in treating dermatological disorders or conditions) is held by Dermira (Canada), Inc.. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8884034?

Dermira (Canada), Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 8884034 expire?

Our index shows an expiration date of Nov 6, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.